Why Next FDA Commissioner Will Have Historically Consequential Role in Cannabis and Psychedelic Policy Dr. Marty Makary resigned as FDA commissioner last week, barely a year after his Senate confirmation. HHS Secretary Robert F. Kennedy Jr. confirmed the departure and...
NLRB Rules that Post-Harvest Workers are Covered by Federal Labor Law May 14, 2026 By Jonathan A. Keselenko , Isabel Celio As we previously blogged, the line between “agricultural” work and “processing” work in the cannabis industry has real consequences for...
Rescheduled but Not Listed: The Outlook for U.S. Cannabis Companies on Major Exchanges May 14, 2026 By Arielle Flamenbaum and Jonathan S. Robbins Introduction[1] On April 23, 2026, the Department of Justice and the Drug Enforcement Administration issued an order...
Marijuana Reclassified: Preliminary Impacts on Homeowners Coverage Issues On April 23, 2026, the United States Department of Justice and Drug Enforcement Administration announced an order reclassifying certain marijuana products from Schedule I to Schedule III under...
Schedule III and the Workplace: How Marijuana Rescheduling Could Reshape Employment Law By Whitt Steineker on May 11, 2026 This is the eleventh of 13 posts describing the impacts of marijuana’s rescheduling. An homage to Phish’s historic run at Madison Square Garden...
Banks Could See New Opportunities If Marijuana Moves to Schedule III 7 May 2026 Marijuana’s proposed move from Schedule I to Schedule III under the Controlled Substances Act has renewed focus on what rescheduling could mean for marijuana-related businesses (MRBs) and...